Large-scale study of NSAIDS finds no link to heart attack
Celebrex is less likely than naproxen and ibuprofen to cause kidney and gastrointestinal problems
Washington
IN 2004, when drugmaker Merck voluntarily pulled the pain-reliever Vioxx off the market amid evidence that it increased the risk of heart attacks, concern naturally turned to its nearly identical rival, Celebrex.
The medication works the same way, by inhibiting production of an enzyme that causes pain and inflammation - as do naproxen, ibuprofen and others in the class of widely used analgesics known as non-steroidal anti-inflammatory drugs (NSAIDS).
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue